Fairvalue-Calculator Fairvalue-Calculator
EN DE

Acumen Pharmaceuticals, Inc (ABOS) Fair Value & Analysis

Healthcare · US · Market cap $169M

Price$2.41
Fair Value$4.39
Upside+82.2%
Quality95/100
Evidence: Low Range $3.29 – $5.49

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Acumen Pharmaceuticals, Inc (ABOS) currently trades at $2.41, while our model-based Fair Value estimate is $4.39 — implying the stock looks roughly 82.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Acumen Pharmaceuticals, Inc (ABOS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.39 versus a price of $2.41 — about +82% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ABOS?
Our 21-model fair value for Acumen Pharmaceuticals, Inc is $4.39 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.41.
What is the quality score of ABOS?
Acumen Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.